Oncodesign Société Anonyme ( ALONC.PA) Stock. Should you Buy or Sell? $ 14.34
-0.02 (-0.14 %)
Oncodesign Société Anonyme Analysis
Updated on 10-09-2022
|52 Week Range
||$7.83 - $14.56
Oncodesign Société Anonyme opened the day at $14.34 which is -0.14 % on yesterday's close.
Oncodesign Société Anonyme has a 52 week high of $14.56 and 52 week low of $7.83, which is a difference of $6.73.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $98.21 M and total net profit is $36206580 which means the company is trading at 2.71 times profit to market capitalization. Theoretically, if you were to buy Oncodesign Société Anonyme for $98.21 M, it would take 15 years to get your money back. Oncodesign Société Anonyme are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
1 D | All
Oncodesign Société Anonyme Stock Forecast - Is Oncodesign Société Anonyme a Buy or Sell?
|DCF Score||Strong Buy|
|DE Score||Strong Buy|
|PE Score||Strong Buy|
|PB Score||Strong Buy|
|Overall Recommendation||Strong Buy|
Growth and Value
|Net Profit Margin
Valuing Oncodesign Société Anonyme
|Price Book Value Ratio
||Price To Book Ratio
|Price To Sales Ratio
||Price Earnings Ratio
How liquid is Oncodesign Société Anonyme
||Debt Equity Ratio
|Long Term Debt To Capitalization
||Total Debt To Capitalization
Latest news about Oncodesign Société Anonyme
About Oncodesign Société Anonyme
CEO : Dr. Philippe Genne
Sector : Healthcare
Industry : Biotechnology
Website : https://www.oncodesign.com
Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. Oncodesign Société Anonyme has a strategic partnership with InterSystems for new treatments in the field of oncology; and Covalab. The company also has a collaboration agreement with TiumBio Co., Ltd. for the research and development of fibrosis drug candidates. Oncodesign Société Anonyme was founded in 1995 and is headquartered in Dijon, France.